London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... a line under the vast majority of Zantac litigation, removing a clear ...

Reported earnings turn negative Expectedly, the company's reported earnings were affected by the payout for Zantac related settlements. I had last written about GSK earlier this month, following ...

Earlier this month, GSK reached a $2.2 billion settlement to end most of its lawsuits in the US, claiming that its discontinued version of the heartburn drug Zantac caused cancer. It took a £1.8 ...

GSK (LSE: GSK) shares fell 3.4% to 1,401p ... $2.2bn settlement in the US to end most of its lawsuits in relation to Zantac, the heartburn drug that allegedly caused cancer. This issue has long ...

GSK shares fell on Wednesday after the ... s agreement to settle the vast majority of US lawsuits against its Zantac drug without admitting liability. Stripping out the litigation costs, GSK ...

GSK said total sales fell by two per cent in the third quarter Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and ...

Excluding its Covid-19 solutions and at constant exchange rates, GSK still expects to deliver top-line growth of 7-9%. With the uncertainty caused by recent Zantac litigation now over, Shore ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance ... recommending routine use of RSV vaccines in all adults 75 and above, instead of its previous recommendation for all adults ...

Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and said its core outlook remained unchanged. Operating profit fell by ...

British pharmaceutical company GSK on Wednesday said ... United States surrounding its Zantac heartburn drug. GSK suffered a loss after tax of £58 million ($75 million) in the July-September ...

GSK (GSK) used its third-quarter trading update to draw a definitive line under the damaging litigation around its now discontinued heartburn medicine Zantac, by agreeing a settlement earlier in ...